Wednesday, 28 March 2018



Stock market investment tips today and Tomorrow, intraday nifty and stocks Tips and call 28 March 2018, Nifty Trading Tips, nifty trend tomorrow, nifty stocks, nifty tips intrans, nifty tips provider, stock market investment for beginners, intraday stock tips, intraday trading intraday stocks watch today, best stocks to buy today and tomorrow, hot stocks to buy now, picks in shares of India 28 March 2018.
--------------------------------------------------------------------------------------------------------------------------------

Indoco Remedies share price dropped 10 percent after the UK healthcare regulator issued seven observations to company's Goa plant I.


The drug maker informed exchanges that, United Kingdom - The Medicines and Healthcare Products Regulatory Agency (UK-MHRA) inspected drug manufacturing facility (plant I in Goa) during March 14-16, 2018.


Subsequent to the inspection, the UK-MHRA issued observations, which include 3 critical and 4 major, the company said.

Goa Plant I manufactures solid dosages, liquid orals and external preparations.

Share of Biocon gained 2.4 percent as it has received marketing authorization approval from the European Commission.

Mylan NV and Biocon announced that their co-developed biosimilar insulin glargine Semglee has received marketing authorization approval from the European Commission following the positive recommendation by the committee of Medicinal products for Human use of European Medicines Agency.

Semglee 100 units/ml 3 mL prefilled disposable pen for people with diabetes, is the first biosimilar from Biocon and Mylan's joint portfolio to be approved in Europe.

Additionally, the Therapeutic Goods Administration (TGA), Australia has also approved biosimilar insulin Glargine Semglee 100 IU/ mL 3 mL prefilled pen for people with diabetes in Australia.

For Quick Trial Contact:
✆ -  09699997717
✆ - 0731-6626222 ✔
Mail: info@ways2capital.com
✆ Join us on WhatsApp @ 89620-00225 ✆
✆ 24/7 Customer Care 1800-3010-2007 (Toll Free)

0 comments:

Post a Comment